Navigation Links
Spartan Bioscience Names Charudutt Shah as Director of Business Development
Date:8/26/2014

Ottawa, Ontario (PRWEB) August 26, 2014

Spartan Bioscience today announced the appointment of Charudutt Shah as its Director of Business Development. Mr. Shah is responsible for expanding distribution of the Spartan RX CYP2C19 System in the United States and international markets. He is also responsible for new business opportunities and strategic initiatives for the company’s rapid sample-to-result genotyping platform.

Prior to joining Spartan, Mr. Shah was the Global Marketing Product Manager for Infectious Disease products at Luminex. He established Luminex’s international sales and distribution channels for molecular diagnostic products. Also, he was responsible for executing commercial strategies to achieve global sales targets. Prior to Luminex, Mr. Shah worked at Life Technologies and Toxikon Corporation.

“We are delighted that Charudutt Shah has joined our management team at Spartan Bioscience,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Charudutt has deep experience in the molecular diagnostic industry and he will have an immediate impact on our business development efforts.”

About the Spartan RX CYP2C19 System
The Spartan RX CYP2C19 System is the first rapid pharmacogenetic test in medicine.(1) It identifies carriers of certain CYP2C19 genetic mutations in 1 hour. The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(2), including important drug classes such as antiplatelet therapies, beta blockers, antidepressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(3,4,5,6)

The Spartan RX CYP2C19 System has FDA 510(k) regulatory clearance for the United States, and CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx/overview/.

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing. Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

1. Roberts JD et al. (2012). Lancet. 379:1705–11.
2. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
3. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
4. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
5. Oh IY et al. (2012). Heart. 98(2):139–44.
6. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12113718.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
2. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
3. Spartan Bioscience Receives FDA Clearance for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs
4. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):